Company intelligence / Profile preview

CKD OTTO Pharma

Jakarta/South Jakarta City/Setiabudi/Karet Kuningan, Jakarta Special Capital Region, Indonesiackd-otto.com ↗

Ownership: Private
Employees: ~125
Development stage: Other

Overview

CKD OTTO Pharma manufactures and markets a portfolio of oncology drugs in Indonesia and exports to MENA, GCC, ASEAN, and East Asia. The company has received GMP certification from Indonesian authorities as well as Halal certification for its oncology manufacturing. Its commercialized products include pemetrexed ("Pemecine"), bortezomib ("Tezobell"), oxaliplatin ("Belloxa"), among others. The company also acts as a contract manufacturer for local partners.

Therapeutic areas: Oncology
Modalities: Small moleculeBiologic
Industry: Biotech

Drug pipeline

4 assets

Bevabell

Unknown

3 more assets in the full pipeline.

Request access →

Partnerships

Chong Kun Dang Pharm Corp.Otto Pharmaceutical Industries/MENSA Group

Beyond the preview

Go deeper on CKD OTTO Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKD OTTO Pharma.

Explore the full profile